RESEARCH ARTICLE

Serological test performance for bovine tuberculosis in cattle from herds with evidence of on-going infection in Northern Ireland

Lyanne McCallan1*, Cathy Brooks1, Claire Barry1, Catherine Couzens1, Fiona J. Young1, Jim McNair1‡, Andrew W. Byrne1,2‡,¤

1 Veterinary Sciences Division, Agri-Food and Biosciences Institute, Stormont, Belfast, Northern Ireland,
2 School of Biological Sciences, Queen’s University Belfast, Belfast, Northern Ireland

☯ These authors contributed equally to this work.
¤ Current address: One-Health Scientific Support Group, Department of Agriculture, Food and the Marine (DAFM), Dublin, Ireland
‡ JMN and AWB are joint senior authors on this work.
* Lyanne.McCallan@afbin.gov.uk

Abstract

The ability to accurately identify infected hosts is the cornerstone of effective disease control and eradication programs. In the case of bovine tuberculosis, accurately identifying infected individual animals has been challenging as all available tests exhibit limited discriminatory ability. Here we assess the utility of two serological tests (IDEXX Mycobacterium bovis Ab test and Enfer multiplex antibody assay) and assess their performance relative to skin test (Single Intradermal Comparative Cervical Tuberculin; SICCT), gamma-interferon (IFNγ) and post-mortem results in a Northern Ireland setting. Furthermore, we describe a case-study where one test was used in conjunction with statutory testing. Serological tests using samples taken prior to SICCT disclosed low proportions of animals as test positive (mean 3% positive), despite the cohort having high proportions with positive SICCT test under standard interpretation (121/921; 13%) or IFNγ (365/922; 40%) results. Furthermore, for animals with a post-mortem record (n = 286), there was a high proportion with TB visible lesions (27%) or with laboratory confirmed infection (25%). As a result, apparent sensitivities within this cohort was very low (<15%), however the tests succeeded in achieving very high specificities (96–100%). During the case-study, 7/670 (1.04%) samples from SICCT negative animals from a large chronically infected herd were serology positive, with a further 17 animals being borderline positive (17/670; 2.54%). Nine of the borderline animals were voluntarily removed, none of which were found to be infected post-mortem (no lesions/bacteriology negative). One serology test negative animal was subsequently found to have lesions at slaughter with M. bovis confirmed in the laboratory.

PLOS ONE | https://doi.org/10.1371/journal.pone.0245655 April 13, 2021 1 / 14
Introduction
Bovine tuberculosis is a globally distributed infectious disease. The impact of infection in cattle at the national and local level can be profound [1, 2]. For example, in Northern Ireland legislation is in place, supported by the United Kingdom and the European Union, to control this disease with the eventual aim of total eradication [3]. In practical terms, disease control across Northern Ireland is implemented through the single intradermal comparative cervical tuberculin (SICCT) test and through carcass inspection at abattoirs where cattle are slaughtered [3]. Animals identified as skin test reactors, either by standard or severe test interpretation, are removed for slaughter by compulsory order and examined post-mortem. Furthermore, all animals slaughtered at abattoirs in Northern Ireland are examined for the presence of tuberculous lesions. Clinical material collected during meat inspection is cultured for the presence of acid-fast bacteria with subsequent identification of species and strain type [4].

Despite the introduction of statutory control measures to identify and remove infected cattle, bovine TB is a persistent problem in Northern Ireland [5]. The epidemiology of disease is complicated by the presence of infection in wildlife [6, 7], and the potential confounding effects of concurrent infections on diagnostic tests [8–10]. Current diagnostic tests applied to cattle are not sufficiently sensitive to identify all infected animals and to remove them before infection is spread [11–14]. This is despite the introduction and widespread use of the interferon gamma release assay (IFNγ) [15] to augment the bovine TB testing regime and to support the front-line tests [16]. In combination, meat inspection, the skin test and IFNγ tests will identify a significant number of infected cattle, but not all [17]. It is therefore important to investigate and validate tests or improved test strategies that will broaden the capacity to identify infected animals.

The development of serology-based assays has been very useful for diagnosis where there is a Th2 type immune response. Such assays can be high throughput, relatively inexpensive and blood samples can be submitted to the laboratory a substantial time after they have been taken from the animal. However, with certain diseases a Th1 type immune responses predominates and antibody tests are largely inappropriate. This is usually the case with bovine TB when following infection, the immune response is influenced by T-cells that direct and maintain a response dominated by IFNγ release [18]. Should disease progress and the burden of infection increase then the immune response changes subtly to a Th2 type where B-cells release antibody [19]. In this situation and in the absence of cell mediated responses that can be exploited using the skin test or the IFNγ assay, an antibody assay may prove useful in the diagnosis of disease. In order to assess the role of antibody tests within a disease control programme that is already based on cell mediated responses, we instigated a study that was centred on bovine TB diseased cattle and at-risk herds. In the study reported here, we compared results from two blind tested serological tests (IDEXX M. bovis Ab test and Enfer multiplex serological test) with the skin test, post-mortem examination, culture confirmation and the IFNγ assay in order to define the utility of serology as a potential diagnostic test. We tested whether there was any association between test outcomes and the sex, age, and breed of animals. We also report on a case-study where one of the serological tests (IDEXX) was used in a large herd where there was a recent chronic history of bTB, and where statutory tests were failing to clear infection.

Materials and methods
Ethical approval
Ethical approval for withdrawal of whole blood samples was not required. Whole blood samples were drawn for bovine IFNγ testing conducted as part of the Northern Ireland TB
eradication programme (in compliance with EU Council Directive 64/432/EEC) with subsequent use in this study approved by the Department of Agriculture, Environment and Rural Affairs (DAERA) in Northern Ireland.

**Whole blood sampling**

Samples intended for analysis were taken from cattle from Northern Ireland TB reactor herds eligible for inclusion in the IFN\(\gamma\) testing scheme operated by the Department for Agriculture, Environment and Rural Affairs (DAERA), Northern Ireland [16, 17]. Animals under six months old were excluded from IFN\(\gamma\) testing and therefore not included in the analysis. Individual blood samples were taken just prior to the inoculation of tuberculins on day one of the skin test and were submitted to the laboratory within 8 hours of collection. Whole blood was removed and stimulated with antigens, to be tested later for IFN\(\gamma\) release. Residual whole blood was centrifuged for 15 minutes to separate plasma from blood cells. Clarified plasma samples were removed individually and stored at -20˚C for serological testing. Plasma samples from 407 animals positive to SICCT or IFN\(\gamma\) and 515 ante-mortem test negative animals (SICCT and IFN\(\gamma\) negative) were selected for serological testing.

**The skin test and carcass inspection at abattoir**

All animals included in the study were skin tested under Annex A, Council Directive 64/432/EEC using Prionics tuberculins (PPD\(_{bovis}\) and PPD\(_{avium}\)). Each tuberculin (0.1mL) was injected intradermally at 3000 IU (PPD\(_{bovis}\)) or 2500 IU (PPD\(_{avium}\)) on day one of the test. Skin thickness measurement, pre- and 72 hours post-injection was used to calculate increased skin thickness and to indicate the diagnostic outcome of the test. Skin test positive cattle (standard interpretation, 4mm) were submitted for slaughter at a designated abattoir in Northern Ireland (WD Meats Ltd) where carcass inspection was carried out to reveal the presence or absence of tuberculous lesions. Carcass inspection was carried out following a standardised protocol defined by DAERA with head (sub-mandibular, parotid and retro-pharyngeal), chest (bronchial and mediastinal), abdominal (mesenteric) and carcass (prescapular, popliteal, iliac and precrural) lymph nodes examined as well as the lungs, pleura and peritoneum. Tissue samples were taken from tissues with and without tuberculous-like lesions and submitted to the culture laboratory. Information pertinent to the skin test, and abattoir inspection as well as laboratory test data was recorded onto the Animal and Public Health Information System (APHIS) operated by DAERA.

**Blinded approach to laboratory tests**

Sample testing was conducted using a single blind study design in which sample information, including herd number, ear tag, and statutory laboratory test results, was withheld from technical staff. This was achieved by assigning arbitrary codes to plasma samples upon collection. The arbitrary codes and corresponding sample information was stored in a database which was controlled by a senior technician. In compliance with data protection, information relating to herd keepers, herds, animals, or samples was withheld.

**The interferon gamma release assay (IFN\(\gamma\) test)**

Whole blood samples were tested for IFN\(\gamma\) release using the Bovigam assay (Prionics, Switzerland) accredited by the United Kingdom Accreditation Service (UKAS). The methodology has been described previously [15]. Briefly, whole blood samples were received into the laboratory within eight hours of removal from the animal and stimulated overnight with pokeweed mitogen (2\(\mu\)g/ml) (internal positive control), phosphate buffered saline (nil antigen control),
PPD<sub>bovis</sub> (72 μg/ml), PPD<sub>avium</sub> (36 μg/ml) and ESAT-6 (0.5 μg/ml). After overnight culture at 37˚C, plasma supernatant fluids were removed and stored prior to test by ELISA. The ELISA was carried out according the manufacturer’s protocol with regards to reagent dilutions, incubation times and plate wash regimes. Individual sample results were accepted and recorded if reagent control and quality assurance standards were met. Those samples with Net PPDb and PPDb-PPDa optical density (OD) indexes of 0.1 or greater were positive and those less than 0.1 OD units were negative.

**Selection of serological tests**

Tests to be evaluated were based on commercial availability and/or through fulfilling the requirements to test samples via a public tender established by AFBI. Two test providers were identified (see below) who satisfied the requirements.

**The IDEXX ELISA for antibodies.**  IDEXX M. bovis ELISA kits were purchased from the manufacturer and the assay was carried out according to the manufacturer’s protocol. The IDEXX ELISA is a commercially available kit. This ELISA has a 96 well microtitre plate format that detects antibodies to two *Mycobacterium tuberculosis* complex antigens (MPB70 and MPB83) known to be serological targets in *Mycobacterium bovis* infections. Briefly, plasma samples were diluted to 1 in 50 in PBS and tested in duplicate. One hundred microliters of reagents were added to wells in duplicate and incubated for 60 minutes then washed 6 times. Assay positive and negative test control reagents were used to validate each microtitre plate and provided data to calculate the test result [sample—nil / positive—nil (S/P ratio)]. Test results were interpreted as per manufacturer’s instructions as follows: an S/P ratio greater or equal to 0.30 was considered positive and a ratio less than 0.3 was negative.

**The Enfer provisioned antibody assay.**  An Enfer provisioned assay was carried out by Enfer staff at their Naas laboratories (Enfer ltd, Naas, Co Kildare). All tests were blinded, with no information on the epidemiological situation (e.g. within-herd prevalence) from which animals were selected provided to Enfer. It should be noted that this Enfer multiplex antibody assay is not a commercially available as a standalone kit, but testing was provided in fulfilment of commercial services as part of a commercial tender to AFBI. The basis for this assay methodology has been described previously [20]. For this study, the defined antigens used in this assay were MPB83, ESAT-6, CFP-10 and MPB70. Enfer scientific printed the bespoke multiplex according to the tender requirements, and carried out the screening, utilising bespoke software to read the multiplex plates [20]. It should also be noted that this study did not include protein fusions and cocktails, which may have been used in other studies employing the Enfer test. Plasma samples were diluted to 1 in 250 (in Enfer sample buffer A) and added to each well and incubated and agitated for 30 minutes. After washing, horseradish conjugated anti-bovine immunoglobulin was added, incubated and washed again. Substrate was added and signals were captured during a 45 second exposure stored as relative light units. The manufacturer recommends that a positive result is recorded when a minimum of any two antigens are test positive. For the purposes of this study the Enfer raw data were interpreted in two different ways. For the Enfer 2ag interpretation, a positive result was recorded if plasma samples were test positive against either MPB70 or MPB83. For the Enfer 4ag interpretation, a positive result was recorded if any two antigens, from MPB70, MPB83, ESAT-6 and CFP-10, were test positive (in line with Enfer low specificity 2ag interpretation).

**Laboratory confirmatory tests for mycobacteria**

Clinical samples removed from animals at slaughter were submitted to a containment level-3 laboratory for preparation, decontamination and inoculation onto solid and liquid media.
Culture procedures at the Statutory TB Laboratories at the Agri-food and Biosciences Institute have been described extensively previously [17, 21]. Tissue structure was disrupted using either ribolysation or grinding with sterile sand in a pestle and mortar. Prior to inoculation, clinical samples were decontaminated using 5% oxalic acid for a maximum of 30 min and washed twice with sterile PBS. Samples were then inoculated onto Lowenstein-Jensen and Stonebrink slopes, as well as into Mycobacterial Growth Indicator Tubes (MGIT) containing PANTA. At 56 days post inoculation, cultures were examined for the presence of acid-fast mycobacteria and if present were further analysed using a spoligotype method [22] to identify mycobacterial species and sub-type.

**Analysis**

Throughout we estimated the Area Under the receiver operator Curve (AUC) as an assessment of the ability of the serological test to discriminate between (apparent) infection states. The AUC is measured on a continuous scale from 0 to 1; an AUC of 0.5 is no better than random, with values >0.7 considered an “adequate” diagnostic [23]. Apparent sensitivity, specificity, positive predictive value and negative predictive value were calculated and reported against alternative/pseudo-gold standards of infection status. Positive Predictive Value (PPV) is the proportion of serological test positives that were positive for the comparator diagnostics (i.e. skin test, gamma interferon, visible lesion, confirmed infection, or combination thereof); Negative Predictive Value (NPV) is the proportion of serological test negatives that were negative for the comparator diagnostics. Agreement amongst tests was explored using the Kappa statistic, a kappa of 1 indicates perfect agreement, whereas a kappa of 0 indicates agreement no better than chance.

Each diagnostic was compared against the skin test (SICCT) result, IFN\(\gamma\) test result and post-mortem status (abattoir findings and microbiological confirmation) of the animal, giving apparent/relative performance indices. We used the definition adopted by Whelan et al. [24] to define “true” infection status. In this case, infection was defined by an animal being positive to the skin test (SICCT standard interpretation), having a visible lesion at slaughter and having a bacteriological confirmation result (positive to histology and/or microbiological culture). Being free of infection, negative animals were negative to SICCT, without lesions at slaughter and without post-mortem bacteriological confirmation. In addition, we used a combination of IFN\(\gamma\), SICCT, VL and culture confirmation, to assess the relative performance of the serology tests.

The relationship between the test status and the independent variables was modelled throughout using binary logit regression models, the outcome being the binary test result [‘positive’ 1; ‘negative’ 0] for each test. A random effect for herd id (to account for potential clustering effects) was included if significant and was tested using a likelihood ratio test. We used \(\chi^2\) tests and binary logit models to assess whether there was any association between animal sex, age at blood test sample, breed type (dairy production Holstein/Friesian vs. other breeds) and the probability of a positive serological test results being disclosed.

Throughout, the dataset was organised using Microsoft excel, while all statistical analysis was undertaken using Stata version 14 (Stata Corp., Texas, USA, 2015).

**Case herd study**

A case study centred on a relatively large (approximately 1000 cattle over the period) dairy herd was carried out to assess the utility of antibody detection where animals were known to be infected and resolution of the problem was proving to be difficult. This particular herd had a seemingly intractable chronic bovine TB problem which originated between 2002 and 2004.
Initially, a relatively small number of bovine TB breakdowns were recorded with subsequent confirmation of infection caused by *Mycobacterium bovis*. From 2008 onward, the rate of skin test positive cattle increased significantly with a total of 148 skin test positive animals identified between December 2008 and May 2015 as well as 2 cases of lesions at routine slaughter, i.e. skin test negative cattle sent for slaughter with confirmed tuberculous lesions disclosed during carcass inspection. Ten out the 148 skin test positive animals were confirmed positive at post-mortem inspection or in the laboratory (histology or bacteriology).

Given the disease history of this herd following routine TB diagnostic investigations, and following approval from DAERA, high risk cohorts of cattle (ante-mortem SICCT negative animals housed or managed alongside TB reactors within this herd) were blood sampled and tested for the presence of antibodies to *M. bovis* using IDEXX serology (OIE approved) in 2016. The fundamental rationale was that detecting antibody in cattle that were skin test negative may indicate the presence of infection in animals that were considered to be anergic, that is, unresponsive to cell mediated tests such as the skin test and IFN-γ assay. In total, 670 samples from cattle were blood sampled having been selected on the basis of being high risk cohorts of animals where the infection was most prevalent.

**Results**

**Agreement and comparison**

Overall, there were 922 animals with test result data; all animals had test results for IFN-γ and IDEXX, 921 had SICCT, 920 had Enfer 2ag and Enfer 4ag results, while 284 animals had a post-mortem result. These animals came from 64 herds with recent bTB breakdowns, with a mean of 14.39 animals tested per herd (Median: 9.5; Std. Dev.: 13.39; Range: 1–76). The proportions of animals positive to each of the individual tests are as follows: 121/921 (13.14%) animals were SICCT positive, 365/922 (39.59%) IFN-γ positive, 40/921 (4.34%) IDEXX positive, 30/921 (3.26%) Enfer 2ag positive, 13/921 (1.41%) Enfer 4ag positive, and 78/284 (27.46%) animals were found to have TB like lesions at post-mortem.

Of the animals with visible lesions found at post-mortem, the proportions deemed positive were not significantly different between the serological test types: IDEXX 10/68 (14.71%), Enfer 2ag 9/68 (13.24%), Enfer 4ag 7/68 (10.29%) (McNemar’s test: Enfer 2ag vs. IDEXX: p = 0.65; Enfer 4ag vs. IDEXX: p = 0.16; Enfer 4ag vs. Enfer 2ag: p = 0.18). Similarly, there were no differences between test types, when using bacteriological confirmation as the infection status diagnostic (p>0.25).

**Serology test performance in comparison with single or combined diagnostic techniques**

The relative performance of the serological tests in comparison with single ante-mortem diagnostics (Table 1), post-mortem diagnostics (Table 2) and combined tests (Tables 3 and 4) are presented below.

Relative to single ante-mortem tests (mean test prevalence 27%; Table 1), the serological tests did not disclose a high proportion of test-positive animals (mean 3% positive). This resulted in the tests exhibiting low apparent sensitivities, averaging 5.73% (range: 4.13% - 9.09%). However, the apparent specificities were always very high, with a mean of 97.82% (96.40% - 99.50%). While there was a significant positive relationship between serological test result and statutory ante-mortem outcome, the discriminatory ability of the tests were always poor (mean AUC: 0.52).

Similar results were found when post-mortem diagnostic techniques were used as the apparent infection status (Table 2). Due to the low sensitivity of the serological antibody tests,
the mean test prevalence was always low (mean test prevalence 4.92%) relative to the proportion of animals with lesions or post-mortem confirmed infection (mean prevalence 26%).

Using similar criteria to Whelan et al. [24] to define animals as “truly” infected and non-infected, we found that the serological tests exhibited poor sensitivity (9.09% - 13.64%; Table 3).

Utilising IFN\textsubscript{γ} test results, as an additional criterion (Table 4), suggested again that the serological tests exhibited low sensitivities, however the three serological tests achieved 100% apparent specificities.

Table 5 gives the breakdown of animal ante-mortem test results in relation to each serological test result. Overall, 8 (8/513; 1.56%), 2 (2/513; 0.39%), and 17 (17/514; 3.31%) animals were ante-mortem test negative, that were deemed serologically test positive to Enfer 2ag, Enfer 4ag and IDEXX, respectively.

Table 6 gives a breakdown of animals with post-mortem confirmed \textit{M. bovis} infection, that were skin-test, IFN\textsubscript{γ}, or either skin-test/ IFN\textsubscript{γ} negative. Enfer 2ag and IDEXX both disclosed as positive 3/19 (15.79%) SICCT false-negative animals. The Enfer 4ag test disclosed two animals of these 19 animals as positive. However, none of the 14 post-mortem confirmed animals that were as IFN\textsubscript{γ} negative were found to be serologically positive. Overall, 6 of the animals with confirmed infection were missed by both SICCT and IFN\textsubscript{γ} tests (6/286; 2.10%), and none of these were disclosed using any of the serological antibody tests.

### Sex, age and breed associations with serological test results

There was a lack of evidence in support for an association between sex on the probability of an animal disclosing as serological positive across all tests (OR 95%CI straddled 0 for all models; \(p>0.05\); Enfer2 ag positive: Males 3.1%; Females 3.3%; Enfer 4ag positive: Males 3.1%; Females 1.1%; IDEXX positive: Males 4.3%; Females 4.4%).

### Table 1. The relative performance of serological tests against statutory ante-mortem tests.

| Test type | n   | Comparator | P-value | AUC  | Sens | Spec | PPV  | NPV  | Prev. (comparator) \(a\) | Test prev. \(b\) |
|-----------|-----|------------|---------|------|------|------|------|------|--------------------------|------------------|
| ENFER 2ag | 919 | Skin test  | 0.008   | 0.52 | 7.44%| 97.40%| 30.00%| 87.40%| 13%                       | 3.26%            |
| ENFER 2ag | 920 | IFN\textsubscript{γ} | 0.009 | 0.52 | 5.22%| 98.00%| 63.30%| 61.20%| 40%                       | 3.26%            |
| ENFER 4ag | 919 | Skin test  | 0.012   | 0.52 | 4.13%| 99.00%| 38.50%| 87.20%| 13%                       | 1.41%            |
| ENFER 4ag | 920 | IFN\textsubscript{γ} | 0.013 | 0.51 | 2.75%| 99.50%| 76.90%| 61.00%| 40%                       | 1.41%            |
| IDEXX    | 921 | Skin test  | 0.008   | 0.53 | 9.09%| 96.40%| 27.50%| 87.50%| 13%                       | 4.34%            |
| IDEXX    | 922 | IFN\textsubscript{γ} | 0.091 | 0.51 | 5.75%| 96.60%| 52.50%| 61.00%| 40%                       | 4.34%            |

Skin test: SICCT standard interpretation.

\(a\) Prev. (comparator): the prevalence of the respective comparator, e.g. skin test etc.

\(b\) Test prev.: the prevalence of the serological test being reported e.g. ENFER 2ag

### Table 2. The relative performance of serological tests against statutory post-mortem diagnostic techniques.

| Test type | n   | Comparator | P-value | AUC  | Sens | Spec | PPV  | NPV  | Prev. (comparator) \(a\) | Test prev. \(b\) |
|-----------|-----|------------|---------|------|------|------|------|------|--------------------------|------------------|
| ENFER 2ag | 283 | Visible lesion | 0.002 | 0.55 | 12.80%| 97.60%| 66.70%| 74.60%| 28%                       | 5.30%            |
| ENFER 2ag | 285 | Confirmed   | 0.003 | 0.55 | 12.70%| 97.20%| 60.00%| 77.00%| 25%                       | 5.26%            |
| ENFER 4ag | 283 | Visible lesion | 0.007 | 0.54 | 8.97%| 98.50%| 70.00%| 68.40%| 28%                       | 3.53%            |
| ENFER 4ag | 285 | Confirmed   | 0.004 | 0.54 | 9.86%| 98.60%| 70.00%| 76.50%| 25%                       | 3.51%            |
| IDEXX    | 284 | Visible lesion | 0.001 | 0.56 | 14.10%| 97.10%| 64.70%| 74.90%| 27%                       | 5.99%            |
| IDEXX    | 286 | Confirmed   | 0.002 | 0.55 | 14.10%| 96.70%| 58.80%| 77.30%| 25%                       | 5.94%            |

https://doi.org/10.1371/journal.pone.0245655.t001

https://doi.org/10.1371/journal.pone.0245655.t002
age effect on the probability of animals disclosing with serological positive test (OR 95%CI straddled 0 for all models; p > 0.08; Enfer 2ag positive vs. negative mean age (SD): 4.2 (3.1), 3.6 (2.8); Enfer 4ag positive vs. negative: 4.8 (3.7), 3.6 (2.8); IDEXX positive vs. negative mean age: 3.7 (3.1), 3.6 (2.8)). Overall, 47% of all animals were Holstein/Friesian dairy breed; 2.8% of these dairy breed animals were positive to Enfer 2ag relative to 3.7% for other breeds (Pearson χ² (df: 1) = 0.612; P = 0.434). For IDEXX, 3.7% of dairy animals were positive, but 4.9% of other breeds were positive (Pearson χ² (df: 1) = 0.827; P = 0.363). There was a greater difference in the proportion disclosed positive between breeds for the Enfer 4ag test, with 0.23% of dairy animals disclosing positive in comparison with 2.5% for other breed animals (Pearson χ² (df:1) = 8.185; P = 0.004). However, only one of the dairy animals (1/433) disclosed with a positive test.

**Case herd study**

Using the manufacturer’s recommended S/P ratio cut-off value of 0.3, seven samples were positive (≥ 0.3) and 663 samples were negative (≤ 0.3). Five samples were clearly positive (> 0.3), two samples were just above the threshold (0.340 and 0.331) and all the remaining samples were negative. However, 17 samples had S/P ratios just below the cut-off value, ranging from 0.271 to 0.113.

Following release of the serology results and discussions with the herd keeper, nine animals were voluntarily surrendered for slaughter. Seven of the nine surrendered animals were serologically positive with S/P ratios ranging from 0.331 to 1.424 and the remaining 2 animals were negative by IDEXX (S/P ratios of 0.157 and 0.223). At post-mortem examination, all cattle were designated non-visibly lesioned and clinical samples from the lung associated lymph nodes were submitted for laboratory tests. All samples were culture negative for *M. bovis*. Subsequent to this serology test-based investigation, one animal which was serology negative and submitted for voluntary slaughter, was examined and found to be visibly lesioned. Clinical samples from this animal were culture positive with *M. bovis* confirmed by spoligotype.

**Discussion**

During the present study, we investigated two serological tests for their relative performance in at-risk herds in Northern Ireland. In comparison with previous work by our group [14], samples for serology testing were taken prior to the SICCT tuberculin test. This sampling approach was decided upon to allow evaluation of serology as a stand-alone test in the absence of skin testing. Whilst serology appears attractive, being relatively low cost and high

| Test type | n  | Comparator                  | P-value | AUC  | Sens  | Spec  | PPV   | NPV   | Prev. (comparator) | Test prev. |
|-----------|----|-----------------------------|---------|------|-------|-------|-------|-------|-------------------|------------|
| ENFER 2ag | 187| SICCT + VL + CONFIRM        | 0.019   | 0.54 | 9.09% | 99.30%| 80.00%| 78.02%| 24%               | 2.67%      |
| ENFER 4ag | 187| SICCT + VL + CONFIRM        | 0.045   | 0.53 | 6.82% | 99.30%| 75.00%| 77.60%| 24%               | 2.14%      |
| IDEXX     | 188| SICCT + VL + CONFIRM        | 0.006   | 0.56 | 13.64%| 97.92%| 66.67%| 78.77%| 31%               | 6.25%      |

Table 3. The relative performance of serological tests against a combination of statutory ante-mortem and post-mortem diagnostic techniques.

https://doi.org/10.1371/journal.pone.0245655.t003

Table 4. The relative performance of serological tests against a combination of statutory ante-mortem and post-mortem diagnostic techniques.

https://doi.org/10.1371/journal.pone.0245655.t004
throughput, this would not necessarily be true if skin testing was required prior to employing serological tests. Overall, our results suggested that the tests can achieve very high levels of apparent specificity. However, our results suggested that these tests failed to identify most animals with pathology or confirmed *M. bovis* infection post-mortem.

Research from Spain has shown when serology tests were evaluated prior to the tuberculin test, serological test performance was reduced relative to tests undertaken with samples after the tuberculin test [25, 26]. Samples taken from a cohort of animals in this Spanish study prior to skin testing suggested that the serology tests examined exhibited a sensitivity of 23.9%-32.6% (*M. bovis* Ab Test (IDEXX) & Enferplex TB assay, respectively). For animals sampled post-skin test, the beneficial anamnestic effect was most pronounced 15 days post-intradermal testing, achieving sensitivity estimates of 66.7%-85.2%. The effect was apparent by the number of animals disclosed as serology test positive when tested prior to skin testing (10.7%; 6/56), 72hrs after skin testing (7.1%; 4/56) and 15 days after testing (57.1%; 32/56).

In the current study, a small proportion of animals were disclosed as serology positive (mean 3% positive). However, during another study in Northern Ireland, we found a higher proportion of animals were disclosed as positive when prevalence was higher (86% SICCT test reactors) and testing occurred after skin testing [14]. The proportion serology positive in that cohort was 39.02–62.20% positive, with apparent sensitivities relative to post-mortem confirmed infection estimated to be 68–82%. These results suggest that maximising the beneficial effects of serology testing may occur if samples are taken after skin testing. Such boosting/priming effects have been described before in cattle in several studies [25, 27–31] and in other species also [32]. Two antigens used in the tests assessed during the present study are known to be boosted by skin testing (MPB83 and MPB70; 35). Such effects have led to some authorities to require follow-up serology testing during statutory tests, for example with camelids in Wales [32].

In the current study, a small proportion of confirmed infected (post-mortem, histology and/or bacteriology) but SICCT negative animals were identified by the serological tests (2-3/19 animals; 10.53%-15.79%). This suggests that, in the absence of other ancillary testing,

### Table 5. Tabulation of the relationship between serological test results, gamma interferon (IFNγ) status by skin test status.

| IFNγ- | IFNγ+ | IFNγ- | IFNγ+ | IFNγ- | IFNγ+ |
|-------|-------|-------|-------|-------|-------|
| SICCT- | Enfer 2ag- | 505 | 272 | Enfer 4ag- | 511 | 279 | IDEXX- | 497 | 274 |
|       | Enfer 2ag+ | 8* | 13 | Enfer 4ag+ | 2* | 6 | IDEXX+ | 17* | 12 |
| SICCT+ | Enfer 2ag- | 39 | 73 | Enfer 4ag- | 41 | 75 | IDEXX- | 40 | 70 |
|       | Enfer 2ag+ | 3 | 6 | Enfer 4ag+ | 1 | 4 | IDEXX+ | 2 | 9 |

* Number of ante-mortem negative animals that were serologically test positive.

https://doi.org/10.1371/journal.pone.0245655.t005

### Table 6. Proportion of confirmed infected animals with positive serological test results, which were missed by SICCT, IFNγ, or both ante mortem bovine TB tests.

| Confirmed infection | ENFER 2ag | ENFER 4ag | IDEXX |
|---------------------|-----------|-----------|-------|
| SICCT- (n)          | 3/19      | 2/19      | 3/19  |
| (% serology positive)| 15.79%    | 10.53%    | 15.79%|
| IFNγ-               | 0/14      | 0/14      | 0/14  |
| (% serology positive)| 0%        | 0%        | 0%    |
| SICCT or IFNγ -     | 0/6       | 0/6       | 0/6   |
| (% serology positive)| 0%        | 0%        | 0%    |

https://doi.org/10.1371/journal.pone.0245655.t006
serological tests could be useful to identify part of this subpopulation. Previous research found of 60 truly infected SICCT negative or inconclusive animals, 53 (88.3%) were disclosed as positive using a multiplex ELISA test [24]. It is hard to account for the relatively poorer detection rate in our study relative to Whelan et al. [24], but the discrepancy can partly be explained by the relatively small number of SICCT negative, M. bovis confirmed animals available in the present study. Employing exact binomial confidence intervals around the proportion, suggests significant uncertainty in our estimate (exact CI: 3.38% - 39.58%).

Another potential reason for the differing outcomes from this study and some other studies using the Enfer test platform, is that there was a limited set of antigens used in the current analysis, namely MPB70, MPB83, ESAT-6 and CFP10. The Enfer multiplex can detect antibody activity to 25 antigens in a single well in a 96-well plate array format [20]. However, to make cross-comparisons, only the most commonly used antigens were used during the present study. Such issues do not arise with the IDEXX M. bovis Ab test, as it is a standard commercial kit. Additionally, differing outcomes from this study and other studies using the IDEXX or Enfer test formats could be ascribed to the fact that this study tested plasma rather than serum, however, it should be noted both tests are marketed for use with bovine serum and plasma.

In Northern Ireland, IFNγ is routinely used in herds with problems clearing infection [16, 17]. We found in this study, that when IFNγ was used instead of, or in parallel with, SICCT, there were no additional M. bovis confirmed animals identified by the serological tests employed. This suggests, where both SICCT and IFNγ are used together, there may be limited opportunities to detect additional missed infected animals using serological tests. Casal et al. [26], however, suggests that in very high prevalence regions there may be value in parallel interpretation of cellular and antibody detection techniques to maximise sensitivity.

During the case study presented, few animals were disclosed as serologically positive from a large herd with a substantial chronic bTB problem. Even with liberal interpretation of the serology test (IDEXX) data, few animals were removed, and tuberculous like lesions were not observed in any of those culled nor could M. bovis be isolated from samples taken from these animals. One animal that was serologically tested, and found negative, was subsequently found to have visible lesions and confirmed for M. bovis post-mortem. This field application of the test in a particularly problematic herd appears to corroborate our other findings presented in this manuscript. However, other case-studies have highlighted benefits of serology as ancillary tests in eradicating TB. For example, a red deer herd in England with a TB outbreak was cleared of infection with the use of both tuberculin testing and serological testing over a 2-year period [33]. The authors suggest that without the additional removal of serologically test positive, the time to eradication may have been significantly increased as well as contributing to maintenance and potential transmission to local wildlife. O’Brien et al. [27] also describes a case-study in a goat herd where skin tests failed to identify all infected animals, with 6/20 slaughtered animals having visible lesions and serologically positive to six M. bovis antigens.

Serological tests could be strategically useful in the case of anergic animals, where advanced and generalised infection is present leading to failure to respond to SICCT due to an impaired cell mediated immunity (CMI) response [12]. However, currently there is limited data on the proportion of animals that could be deemed anergic in Northern Ireland farms. Potentially, the repeated application of SICCT testing over an animal’s lifetime could lead to desensitisation [12, 34], again resulting in false negatives. When we looked at the impact of age on the probability of disclosure, we found no significant variation in our cohort. We found some weak evidence for variation in disclosure depending on breed-type, with generally Friesian/ Holstein cattle exhibiting lower probability of disclosing serology positive (though this effect appeared to be only large on one of the tests, Enfer 4ag). Further research is required to ascertain whether this is a robust finding--there is significant uncertainty with the current study
given the very small numbers of animals serologically test-positive. However, previous research has suggested that there may be significant variation in *M. bovis* susceptibility and pathology across breeds [35, 36], which could be partially attributed to immunological or genetic variation [37], or other management factors.

**Conclusions**

We have shown that two available serological tests, when applied to cattle populations with moderate prevalence and with samples taken prior to tuberculin testing, can exhibit limited apparent sensitivities but very high specificities. Serological tests can disclose additional test-positive animals when used in parallel with the skin tuberculin test. However, we found in this study, that when IFNγ was used instead of, or in parallel with, SICCT, there were no *M. bovis* confirmed animals identified by the serological tests employed. This suggests, where both SICCT and IFNγ are used together, there may be limited opportunities to detect additional missed infected animals via the serological tests examined when samples were taken prior to skin testing. From a perspective of a country with an ongoing extensive eradication scheme, future strategic use of serology may be limited to: 1. extreme cases of very large breakdowns within herds leading to high within-herd bTB prevalence, 2. in problem herds where IFNγ testing is unavailable, and 3. chronically infected herds where blood samples are taken after tuberculin testing to maximise sensitivity gained from any anamnestic effects.

**Supporting information**

S1 Table. Serological study raw data including IFNγ, serological, SICCT test results and abattoir findings. 1 = positive; 0 = negative.

(XLSX)

**Acknowledgments**

We thank the TB Immunology, TB Culture and TB Molecular laboratories at AFBI for their expertise in interferon gamma testing, bacteriology, and molecular confirmation techniques, respectively, as well as Jordon Graham for his assistance with capturing data from the Animal and Public Health Information System (APHIS).

**Author Contributions**

**Conceptualization:** Lyanne McCallan, Fiona J. Young, Jim McNair, Andrew W. Byrne.

**Data curation:** Lyanne McCallan, Cathy Brooks, Claire Barry, Catherine Couzens, Jim McNair.

**Formal analysis:** Lyanne McCallan, Jim McNair, Andrew W. Byrne.

**Funding acquisition:** Jim McNair.

**Investigation:** Claire Barry.

**Methodology:** Lyanne McCallan, Cathy Brooks, Claire Barry, Catherine Couzens, Fiona J. Young, Jim McNair.

**Project administration:** Fiona J. Young, Jim McNair, Andrew W. Byrne.

**Supervision:** Lyanne McCallan, Fiona J. Young, Jim McNair.

**Validation:** Lyanne McCallan, Jim McNair.
Writing – original draft: Lyanne McCallan, Jim McNair, Andrew W. Byrne.

Writing – review & editing: Lyanne McCallan, Cathy Brooks, Claire Barry, Fiona J. Young, Jim McNair, Andrew W. Byrne.

References
1. Zinsstag J, Schelling E, Roth F, Kazwala RR. 2006. Economics of bovine tuberculosis. In Thoen CO (Ed.), Mycobacterium bovis infection in animals and humans. 2nd edition. Blackwell Publishing; 2006. pp. 68–83.
2. O’Reilly LM, Daborn CJ. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber Lung Dis. 1995; 76: 1–46. https://doi.org/10.1016/0962-8479(95)90591-x PMID: 7579326
3. Abernethy DA, Denny GO, Menzies FD, McGuckian P, Honhold N, Roberts AR. The Northern Ireland programme for the control and eradication of Mycobacterium bovis. Vet Microbiol. 2006; 112: 231–237. https://doi.org/10.1016/j.vetmic.2005.11.023 PMID: 16326042
4. Skuce RA, McDowell SW, Mallon TR, Luke B, Breadon EL, Lagan PL, et al. Discrimination of isolates of Mycobacterium bovis in Northern Ireland on the basis of variable numbers of tandem repeats (VNTRs). Vet Rec. 2005; 157: 501. https://doi.org/10.1136/vr.157.17.501 PMID: 16242331
5. Abernethy DA, Upton P, Higgins IM, McGrath G, Goodchild AV, Rolfe SJ, et al. Bovine tuberculosis trends in the UK and the Republic of Ireland, 1995–2010. Vet Rec. 2013; 172: 312. https://doi.org/10.1136/vr.100969 PMID: 23292950
6. Palmer MV. Tuberculosis: a re-emerging disease at the interface of domestic animals and wildlife. In Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission. Springer Berlin Heidelberg. 2007. pp. 195–215.
7. Byrne AW, White PW, McGrath G, O’Keeffe J, Martin SW. 2014. Risk of tuberculosis cattle herd breakdowns in Ireland: effects of badger culling effort, density and historic large-scale interventions. Vet Res. 2014; 45: 1. https://doi.org/10.1186/1297-9716-45-1 PMID: 24393488
8. Byrne AW, Graham J, Brown C, Donaghy A, Guelbenzu-Gonzalo M, McNair J, et al. 2017. Bovine tuberculosis visible lesions in cattle culled during herd breakdowns: the effects of individual characteristics, trade movement and co-infection. BMC Vet Res. 2017; 13(1): 400. https://doi.org/10.1186/s12917-017-1321-z PMID: 29284483
9. Byrne AW, Guelbenzu-Gonzalo M, Strain SA, McBride S, Graham J, Lahuerta-Marin A, et al. Assessment of concurrent infection with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis: a herd-level risk factor analysis from Northern Ireland. Prev Vet Medicine. 2017; 141: 38–47.
10. Álvarez J, De Juan L, Bezos J, Romero B, Sáez JL, Marqués S, et al. Effect of paratuberculosis on the diagnosis of bovine tuberculosis in a cattle herd with a mixed infection using interferon-gamma detection assay. Vet Microbiol. 2009; 135: 389–393. https://doi.org/10.1016/j.vetmic.2008.09.060 PMID: 18986776
11. Pollock JM, Welsh MD, McNair J. Immune responses in bovine tuberculosis: towards new strategies for the diagnosis and control of disease. Vet Immunol Immunopathol. 2005; 108: 37–43. https://doi.org/10.1016/j.vetimm.2005.08.012 PMID: 16150494
12. de la Rua-Domenech R, Goodchild AT, Vordermeier HM, Hewinson RG, Christiansen KH, Clifton-Hadley RS. Ante mortem diagnosis of tuberculosis in cattle: a review of the tuberculin tests, γ-interferon assay and other ancillary diagnostic techniques. Res Vet Sci. 2006; 81: 190–210. https://doi.org/10.1016/j.rvsc.2005.11.005 PMID: 16513150
13. Lahuerta-Marín A, Milne G, McNair J, Skuce R., McBride S, Menzies F, et al. Bayesian Latent Class estimation of sensitivity and specificity parameters of diagnostic tests for bovine tuberculosis in chronically infected herds in Northern Ireland. Vet J. 2018; 238: 15–21. https://doi.org/10.1016/j.tvjl.2018.04.019 PMID: 30103911
14. McCallan L, Brooks C, Couzens C, Young F, McNair J, Byrne AW. Assessment of serological tests for diagnosis of bovine tuberculosis. Vet Rec. 2017; 181: 90. https://doi.org/10.1136/vetrec.v184.1 PMID: 28386030
15. Welsh MD, McNair J, McDowell SWJ, Buchanan J, Hill R, McBride SH, et al. The Northern Ireland Interferon-gamma (IFN-g) Testing Programme. Cattle Practice. 2008; 16: 136–139.
16. Lahuerta-Marín A, Gallagher M, McBride S, Skuce R, Menzies F, McNair J, et al. Should they stay, or should they go? Relative future risk of bovine tuberculosis for interferon-gamma test-positive cattle left on farms. Vet Res. 2015; 46: 1. https://doi.org/10.1186/s13567-014-0124-5 PMID: 25582708
17. Lahuerta-Marín A, McNair J, Skuce R, McBride S, Allen M, Strain SA, et al. Risk factors for failure to detect bovine tuberculosis in cattle from infected herds across Northern Ireland (2004–2010). Res Vet Sci. 2016; 107: 233–239. https://doi.org/10.1016/j.rvsc.2016.06.014 PMID: 27474001

18. Welsh MD, Cunningham RT, Corbett DM, Girvin RM, McNair J, Skuce RA, et al. Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis. Immunol. 2005; 114: 101–111. https://doi.org/10.1111/j.1365-2567.2004.02003.x PMID: 15606800

19. Pollock JM, Neill SD. 2002. Mycobacterium bovis infection and tuberculosis in cattle. Vet J. 2002; 163: 115–127. https://doi.org/10.1053/vjl.2001.0655 PMID: 12093187

20. Whelan C, Shuralev E, O’Keefe G, Hyland P, Kwok HF, Snoddy P, et al. Multiplex immunoassay for serological diagnosis of Mycobacterium bovis infection in cattle. Clin Vac Immunol. 2008; 15: 1834–1838. https://doi.org/10.1128/CVI.00238-08 PMID: 18927068

21. Stewart LD, McNair J, McCallan L, Gordon A, Grant IR. Improved detection of Mycobacterium bovis infection in bovine lymph node tissue using immunomagnetic separation (IMS)-based methods. PloS One. 2013; 8: 3. https://doi.org/10.1371/journal.pone.0058374 PMID: 23469275

22. Kamerbeek J, Schouls LE, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997; 35: 907–14. https://doi.org/10.1128/JCM.35.4.907-914.1997 PMID: 9157152

23. Hosmer DW, Lemeshow S. Applied logistic regression. John Wiley & Sons; 2004.

24. Whelan C, Whelan AO, Shuralev E, Kwok HF, Hewinson G, Clarke J, et al. Performance of the Enferplex TB assay with cattle in Great Britain and assessment of its suitability as a test to distinguish infected and vaccinated animals. Clin Vaccine Immunol. 2010; 17: 813–817. https://doi.org/10.1128/CVI.00489-09 PMID: 20219883

25. Casal C, Infantes JA, Risalde MA, Díez-Guerrier A, Domínguez M, Moreno I, et al. Antibody detection tests improve the sensitivity of tuberculosis diagnosis in cattle. Res Vet Sci. 2017; 112: 214–21. https://doi.org/10.1016/j.rvsc.2017.05.012 PMID: 28521256

26. Casal C, Díez-Guerrier A, Álvarez J, Rodriguez-Campos S, Mateos A, Linscott R, et al. Strategic use of serology for the diagnosis of bovine tuberculosis after intradermal skin testing. Vet Micro, 2014; 170: 342–351.

27. O’Brien A, Whelan C, Clarke JB, Hayton A, Watt NJ, Harkiss GD. Serological Analysis of Tuberculosis in Goats by Use of the Enferplex Caprine TB Multiplex Test. Clin Vaccine Immunol. 2017; 24: 2. https://doi.org/10.1128/CVI.00518-16 PMID: 27974399

28. Waters WR, Palmer MV, Thacker TC, Bannantine JP, Vordermeier HM, Hewinson RG, et al. Early antibody responses to experimental Mycobacterium bovis infection of cattle. Clin Vaccine Immunol. 2006; 13: 648–654. https://doi.org/10.1128/CVI.00061-06 PMID: 16760322

29. Waters WR, Maggioli MF, McGill J, Lyashchenko KP, Palmer MV. Relevance of bovine tuberculosis research to the understanding of human disease: Historical perspectives, approaches and immunologic mechanisms. Vet Immunol Immunopathol. 2014; 159: 113–132. https://doi.org/10.1016/j.vetimm.2014.02.009 PMID: 24636301

30. Waters WR, Thacker TC, Nelson JT, DiCarlo DM, Maggioli MF, Greenwald R, et al. Virulence of two strains of Mycobacterium bovis in cattle following aerosol infection. J Com Pathol. 2014; 151: 410–419. https://doi.org/10.1016/j.jcpa.2014.08.007 PMID: 25306158

31. Waters WR, Palmer MV, Stafne MR, Bass KE, Maggioli MF, Thacker TC, et al. Effects of serial skin testing with purified protein derivative on the level and quality of antibodies to complex and defined antigens in Mycobacterium bovis-infected cattle. Clin Vaccine Immunol. 2015; 16: 641–649.

32. de la Rua-Domenech R, Rhodes S, Rolle S, Vordermeier M. The anamnestic boost effect of the skin test on antibody responses to Mycobacterium bovis in camelds—summary of evidence. 2017. Available from: http://www.alpacatb.com/anamnestic%20antibody%20response%20scientific%20evidence%20(2).pdf

33. Busch F, Bannerman F, Liggett S, Griffin F, Clarke J, Lyashchenko KP, et al. Control of bovine tuberculosis in a farmed red deer herd in England. Vet Rec. 2017; 180: 68. https://doi.org/10.1136/vr.103930 PMID: 28100768

34. Monaghan ML, Doherty ML, Collins JD, Kazda JF, Quinn PJ. The tuberculin test. Vet Microbiol. 1994; 40: 111–124. https://doi.org/10.1016/0378-1135(94)90050-7 PMID: 8073619

35. Ameni G, Aseffa A, Engers H, Young D, Gordon S, Hewinson G, et al. High prevalence and increased severity of pathology of bovine tuberculosis in Holsteins compared to zebu breeds under field cattle husbandry in central Ethiopia. Clin Vaccine Immunol. 2007; 14:1356–1361. https://doi.org/10.1128/CVI.00205-07 PMID: 17761523
36. Wright DM, Allen AR, Mallon TR, McDowell SW, Bishop SC, Glass EJ, et al. Field-isolated genotypes of *Mycobacterium bovis* vary in virulence and influence case pathology but do not affect outbreak size. PloS One. 2013; 8:e74503. https://doi.org/10.1371/journal.pone.0074503 PMID: 24086351

37. Allen AR, Skuce RA, Byrne AW. Bovine tuberculosis in Britain and Ireland–A Perfect Storm? The confluence of potential ecological and epidemiological impediments to controlling a chronic infectious disease. Front Vet Sci. 2018; 5: 109. https://doi.org/10.3389/fvets.2018.00109 PMID: 29951489